Agenus is actively involved in the research and development of immune checkpoint antibodies, which are designed to enhance the body's natural ability to fight cancer. This segment focuses on developing novel antibodies that target key immune checkpoints, such as CTLA-4, PD-1, and TIGIT, to unleash the full potential of the immune system against tumors. The company's lead candidates, including botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1), are undergoing clinical trials across various cancer types. Agenus employs its Retrocyte Display technology to identify and develop fully human and humanized monoclonal antibodies with optimized efficacy and safety profiles. The ultimate goal is to provide patients with more effective and durable cancer treatments by overcoming immune suppression and promoting robust anti-tumor responses. Partnerships and collaborations are essential to accelerate the development and commercialization of these innovative immunotherapies.

Agenus is dedicated to developing innovative cancer vaccines designed to stimulate the immune system to recognize and destroy cancer cells. This segment focuses on creating personalized and off-the-shelf vaccine candidates that target tumor-specific antigens, thereby eliciting potent anti-tumor immune responses. The company's vaccine programs include Prophage, a vaccine candidate targeting heat shock protein peptide complexes, and other novel vaccine platforms. Agenus leverages its expertise in antigen discovery, adjuvant development, and vaccine formulation to optimize the immunogenicity and efficacy of its cancer vaccines. Clinical trials are underway to evaluate the safety and efficacy of these vaccines in various cancer settings. The aim is to provide patients with a proactive approach to cancer treatment by harnessing the power of the immune system to prevent recurrence and improve long-term survival. Strategic collaborations and partnerships are crucial for advancing the development and commercialization of these cutting-edge cancer vaccines.

Agenus is a leader in the development and manufacturing of vaccine adjuvants, which are critical components that enhance the immune response to vaccines. This segment focuses on producing high-quality adjuvants, such as QS-21 Stimulon, a saponin-based adjuvant derived from the bark of the Quillaja saponaria tree. QS-21 Stimulon has been shown to enhance both humoral and cellular immune responses, making it a valuable tool for improving the efficacy of vaccines against infectious diseases and cancer. Agenus is committed to providing scalable and affordable vaccine adjuvants to enhance global health. The company's adjuvant technologies are used in various vaccine formulations developed by Agenus and its partners. By optimizing adjuvant formulations and delivery methods, Agenus aims to improve the immunogenicity, durability, and breadth of vaccine-induced immune responses. Strategic partnerships and collaborations are essential for expanding the use of Agenus' adjuvants in vaccine development programs worldwide.